Mounjaro While Pregnant: What You Need to Know

Step 1, Stop Mounjaro and tell your prescriber straight away

If you find out you are pregnant while on Mounjaro, the first thing to do is stop taking it and contact your prescriber or GP the same day or as early as possible. This is not a situation where you wait for your next scheduled review. Tirzepatide's half-life means the medicine clears slowly from the body, so the timing of your last dose relative to your pregnancy is relevant clinical information your doctor will want to record.

The NHS medicines page for tirzepatide states plainly that Mounjaro should not be used in pregnancy, and the prescribing information reflects the same position. There is no established safe dose in human pregnancy. Animal reproductive toxicity data raised concerns at exposures comparable to therapeutic human doses, which is why regulators drew a firm line. Your GP or obstetric team can advise on any monitoring that might be appropriate based on how far along you are and how long you had been taking the medicine.

You may also want to note this in your maternity records when booking your first antenatal appointment. Being transparent with your midwife about recent medicines, including tirzepatide, helps ensure your antenatal care is tailored correctly from the start.

Step 2, Understand what is known and what is still uncertain

The honest answer to what Mounjaro does in human pregnancy is that we do not yet have enough data to say. Tirzepatide is a relatively new medicine; large randomised trials specifically in pregnant women have not been conducted and, for obvious ethical reasons, are unlikely to be. What we do have is: animal studies showing embryo-foetal toxicity, reproductive harm and reduced foetal weight at relevant doses; a pharmacological mechanism that affects hormones involved in metabolism and appetite; and a pharmacokinetic profile that means the medicine does not leave the body immediately on stopping.

For broader context on how GLP-1 medicines interact with pregnancy-related physiology, the NHS England guidance on weight-management injections discusses the importance of contraception and stopping treatment before conception. The uncertainty here is not a reason to panic (many people have stopped Mounjaro and gone on to healthy pregnancies) but it does mean your clinical team should know, and it means contributing to post-marketing safety registries is genuinely useful to future patients.

If you were pregnant while on Mounjaro and want to understand the question of how that might affect fertility or conception timelines, there is more detail on the relationship between Mounjaro and getting pregnant on a dedicated page.

Step 3, Think about contraception now, if you are not already pregnant but are planning to be

If you are currently taking Mounjaro and are thinking about trying to conceive, the guidance is to stop the medicine before you start trying. The SmPC does not specify a minimum washout period before conception with precision, but the advice to stop in advance of attempting pregnancy is consistent across clinical guidance. Discuss the timing with your prescriber so that your weight-management plan can be adjusted appropriately, stopping abruptly without a plan is not necessary, but stopping with a plan is sensible.

There is also a specific contraception consideration that sits earlier in this story. Because Mounjaro slows gastric emptying, the absorption of oral contraceptive pills may be reduced during the first four weeks of treatment and for four weeks after any dose increase. NHS guidance recommends adding a non-oral method of contraception (such as condoms) during those windows. A missed or under-absorbed pill in those early weeks is a realistic route to an unplanned pregnancy while on Mounjaro, so this is worth taking seriously at the start of treatment. For anyone who found themselves pregnant while already on Mounjaro, that page covers the situation in more detail.

For the broader question of whether tirzepatide affects fertility itself, the tirzepatide and pregnancy page sets out what the clinical evidence does and does not tell us.

Weight management after pregnancy, when can treatment resume?

Breastfeeding is another period during which Mounjaro is not recommended. Tirzepatide is not known to pass into human breast milk, but the absence of data is not clearance; the precautionary position from regulators is that it should not be used while breastfeeding. Once you have finished breastfeeding and your clinical picture has settled, a conversation with a prescriber about whether weight-management treatment is appropriate for you can restart from scratch.

If your pen is still sitting in the fridge door from before you became pregnant, it should not simply be restarted without a fresh clinical assessment. Any return to treatment at that point involves a new consultation, a review of where you are medically, and a decision by a prescriber, not a continuation of where you left off. At nume, every repeat order receives individual clinical review before anything is dispatched; that principle applies equally to someone returning to treatment after a significant life event.

The weight-loss treatment overview explains the options available to adults who are at a suitable stage to consider starting or restarting. And if you have questions about the process at nume specifically, the clinical team page gives a sense of who reviews consultations. Separately, the Mounjaro overview page covers the medicine's licence, mechanism and trial evidence for anyone considering it fresh.

If you have other questions about what is and is not safe alongside Mounjaro (including lifestyle factors) the guidance on alcohol and Mounjaro is one example of the situation-specific information available, and anyone with an existing eye condition may also want to read about how Mounjaro relates to diabetic retinopathy before starting or resuming treatment.